2024全年财务结果：截至2024年12月31日，研发费用为5,900万美元，相比2023年同期的3,390万美元增长了2,510万美元，主要是由于与癌后药物相关的Phase 2 STRIDES试验发展及生产费用增加了2,280万美元。2024年全年一般和行政费用为1,920万美元，较2023年同期的1,450万美元增加了470万美元，这主要是由于2024年发放的股票期权补偿费用的增加。2024年净亏损为7,110万美元，每个普通股基本和摊薄后的亏损为$(6.63)，与2023年同期每个普通股基本和摊薄后的亏损为$(38.17)相比有所减少。截至2024年12月31日，BioAge拥有约3.543亿美元的现金和现金等价物。根据目前的运营计划，预计现有现金和现金等价物足以支持运营和资本支出至2029年。

以上内容来自Benzinga Earnings专栏，原文如下：

Full Year 2024 Financial Results

Research and development expenses were $59.0 million for the year ended December 31, 2024, compared to $33.9 million for the same period in 2023. The $25.1 million increase in research and development expenses was primarily attributable to a $22.8 million increase in costs related to the development of azelaprag driven by the Phase 2 STRIDES trial and costs related to the manufacture of azelaprag.

General and administrative expenses were $19.2 million for the year ended December 31, 2024, compared to $14.5 million for the same period in 2023. The $4.7 million increase was primarily attributable to an increase in stock-based compensation expense associated with option grants issued in 2024 to employees, executives, board members and advisors.

Net loss was $71.1 million for the year ended December 31, 2024, or $6.63 per weighted-average common share outstanding, basic and diluted, compared to a net loss of $63.9 million, or $38.17 per weighted-average common share outstanding, basic and diluted, for the same period in 2023.

As of December 31, 2024, BioAge had approximately $354.3 million in cash and cash equivalents. Based on our current operating plan, BioAge estimates that existing cash and cash equivalents will be sufficient to fund operations and capital expenses through 2029.